Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Breast cancer chemoprevention: beyond tamoxifen
Autore:
Fabian, CJ;
Indirizzi:
Univ Kansas, Med Ctr, Kansas City, KS 66160 USA Univ Kansas Kansas City KS USA 66160 , Med Ctr, Kansas City, KS 66160 USA
Titolo Testata:
BREAST CANCER RESEARCH
fascicolo: 2, volume: 3, anno: 2001,
pagine: 99 - 103
SICI:
1465-542X(2001)3:2<99:BCCBT>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
SURGICAL-ADJUVANT-BREAST; ESTROGEN-RECEPTOR-ALPHA; BOWEL-PROJECT P-1; RETINOIC ACID; MAMMARY CARCINOGENESIS; POSTMENOPAUSAL WOMEN; PERILLYL ALCOHOL; RANDOMIZED TRIAL; CELLS; RISK;
Keywords:
breast cancer chemoprevention; clinical models; new agents;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
62
Recensione:
Indirizzi per estratti:
Indirizzo: Fabian, CJ Univ Kansas, Med Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA Univ Kansas 3901 Rainbow Blvd Kansas City KS USA 66160 6160 USA
Citazione:
C.J. Fabian, "Breast cancer chemoprevention: beyond tamoxifen", BREAST CA R, 3(2), 2001, pp. 99-103

Abstract

A large number of new potential chemoprevention agents are available that target molecular abnormalities found in estrogen receptor (ER)-negative and/or ER-positive precancerous breast tissue and have side effect profiles that differ from tamoxifen. Classes of agents currently undergoing evaluationin clinical prevention trials or those for which testing is planned in thenear future include new selective ER modulators, aromatase inactivators/inhibitors, gonadotrophin-releasing hormone agonists, monoterpenes, isoflavones, retinoids, rexinoids, vitamin D derivatives, and inhibitors of tyrosinekinase, cyclooxygenase-2, and polyamine synthesis. New clinical testing models will use morphological and molecular biomarkers to select candidates at highest short-term risk, to predict the response to a particular class ofagent, and to assess the response in phase II prevention trials. If validated, morphological and molecular markers could eventually replace cancer incidence as an indicator of efficacy in future phase III trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/21 alle ore 03:52:21